Sugi Predict

Sugi Predict / Compounds / SCHEMBL7079252

SCHEMBL7079252

SCHEMBL7079252

CC(C)(C)OC(=O)N[C@@H](CS)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ CTSK P43235 10/20 0.46
▸ CTSS P25774 7/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ HDAC4 P56524 2/20 0.43
▸ HDAC1 Q13547 2/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ CYP2D6 P10635 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6237621 1.00 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL295886 0.91 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1341495 0.91 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL3819517 0.91 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1455923 0.88 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1455920 0.88 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL474893 0.86 HDAC4 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL30788769 0.86 HDAC4 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL474895 0.86 HDAC4 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL377348 0.85 MAPT (0.55) CYP1A2CYP2C9CYP2C19HTTCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4071135-B1 ETELCALCETIDE INTERMEDIATE AND METHOD FOR SYNTHESIZING ETELCALCETIDE ASYMCHEM LAB TIANJIN CO LTD (CN) 2024-11-27 — — EP claimed
US-20230021514-A1 Etelcalcetide intermediate and method for synthesizing etelcalcetide ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) 2023-01-26 — — US claimed
EP-4071135-A1 ETELCALCETIDE INTERMEDIATE AND METHOD FOR SYNTHESIZING ETELCALCETIDE Asymchem Laboratories (Tianjin) Co., Ltd. (CN) 2022-10-12 — — EP claimed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 — — EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 — — US disclosed
CN-114585637-B MASP-inhibitory compounds and uses thereof 拜耳公司 2025-04-15 — — CN disclosed
EP-4071135-B1 ETELCALCETIDE INTERMEDIATE AND METHOD FOR SYNTHESIZING ETELCALCETIDE ASYMCHEM LAB TIANJIN CO LTD (CN) 2024-11-27 — — EP disclosed
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 — — US disclosed
CN-111954525-B Prodrugs of fused bicyclic C5aR antagonists 凯莫森特里克斯股份有限公司 2023-12-26 — — CN disclosed
EP-3937924-B1 COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR TREATING HYPERTENSION OR HEART FAILURE QUANTUM GENOMICS (FR) 2023-09-06 — — EP disclosed
US-11667675-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2023-06-06 — — US disclosed
EP-0958277-B1 NITRIC OXIDE SYNTHASE INHIBITORS GLAXO GROUP LTD (GB) 2001-11-21 — — EP disclosed
EP-1084104-A1 NITRIC OXIDE SYNTHASE INHIBITORS GLAXO GROUP LIMITED (GB) 2001-03-21 — — EP disclosed
WO-1999062875-A1 NITRIC OXIDE SYNTHASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-12-09 — — WO disclosed
EP-0958277-A1 NITRIC OXIDE SYNTHASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-11-24 — — EP disclosed
WO-1998030537-A1 NITRIC OXIDE SYNTHASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-07-16 — — WO disclosed
US-5770710-A REACTING METHYLTRITHIO ANTIBIOTIC LL-E32288 DERIVATIVE WITH MERCAPTAN COMPOUND AMERICAN CYANAMID COMPANY (US) 1998-06-23 — — US disclosed
US-5606040-A DERIVATIZED OLIGOSACCHARIDE ANTIBIOTICS WITH CHROMOPHORE AMERICAN CYANAMID COMPANY (US) 1997-02-25 — — US disclosed
EP-0153391-A1 POLY-CATION SALTS OF 4-O-POLYHEXAOSE-THIO-ALKYLENE SULFATE DERIVATIVES AMERICAN CYANAMID COMPANY (US) 1985-09-04 — — EP disclosed
WO-1985000971-A1 POLY-CATION SALTS OF 4-O-POLYHEXAOSE-THIO-ALKYLENE SULFATE DERIVATIVES AMERICAN CYANAMID COMPANY (US) 1985-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 CYP1A2 4511/4885CYP2C9 4770/4885CYP2C19 4587/4885
US-11667675-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 CYP1A2 4511/4885CYP2C9 4770/4885CYP2C19 4587/4885
US-20240124522-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF MASP2, SERPINB1, SPINT2 CYP1A2 4511/4885CYP2C9 4770/4885CYP2C19 4587/4885
US-20230021514-A1 Etelcalcetide intermediate and method for synthesizing etelcalcetide PTMS, CTSS, SOST CYP1A2 2956/4885CYP2C9 427/4885CYP2C19 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.